Targeting Mechanism of a Novel Liver-targeting Interferon IFN-CSP Involves Liver Heparan Sulfate Proteoglycan
- PMID: 26310618
- DOI: 10.2174/1567201812666150827123602
Targeting Mechanism of a Novel Liver-targeting Interferon IFN-CSP Involves Liver Heparan Sulfate Proteoglycan
Abstract
Background: In our previous study, a novel liver-targeting interferon (IFN-CSP) combining IFN α2b with plasmodium region I-plus peptide was successfully designed and prepared with Escherichia coli expression systems. The purified IFN-CSP showed anti-HBV activity and liver-targeting potentiality. The present investigation was designed to investigate the molecular mechanisms responsible for liver-targeting of IFN-CSP.
Methods: The binding site of IFN-CSP in hepatocytes was assayed by immunofluorescent staining. The correspondence of HSPG distribution and the pattern of IFN-CSP binding in liver tissue were determined using a confocal laser scanning microscope. Both the hepatocytes and liver tissue were using as model to investigate the effect of enzyme and soluble glycosaminoglycan on IFN-CSP binding using flow cytometry and fluorescence microscope.
Results: Studies of hepatocytes demonstrated that the localization of IFN-CSP in hepatocytes was the plasma membrane. Studies of liver tissue slices showed that IFN-CSP bound to liver tissue in a pattern similar to the distribution of heparan sulfate proteoglycan (HSPG) immunoreactivity. Pretreatment of hepatocytes and liver slices with heparinase reduced the binding of IFN-CSP to HepG2.2.15 cells and liver slices. Coincubation of IFN-CSP with heparin markedly inhibited IFNCSP binding to HepG2.2.15 cells and liver slices.
Conclusion: These results indicate that the molecular mechanisms responsible for IFN-CSP targeting involve binding to HSPG of hepatocytes and liver.
Similar articles
-
Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver.J Pharm Sci. 2008 Aug;97(8):3257-73. doi: 10.1002/jps.21211. J Pharm Sci. 2008. PMID: 17932963
-
IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway.Biomed Res Int. 2015;2015:959684. doi: 10.1155/2015/959684. Epub 2015 Mar 16. Biomed Res Int. 2015. PMID: 25861653 Free PMC article.
-
High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo.BMC Biotechnol. 2015 Jun 12;15:54. doi: 10.1186/s12896-015-0177-1. BMC Biotechnol. 2015. PMID: 26063245 Free PMC article.
-
Malaria sporozoites and chylomicron remnants compete for binding sites in the liver.Behring Inst Mitt. 1997 Mar;(99):85-9. Behring Inst Mitt. 1997. PMID: 9303206 Review.
-
Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins.Prog Mol Biol Transl Sci. 2010;93:213-33. doi: 10.1016/S1877-1173(10)93010-X. Prog Mol Biol Transl Sci. 2010. PMID: 20807647 Review.
Cited by
-
Production of bioactive liver-targeting interferon Mu-IFN-CSP by soluble prokaryotic expression.AMB Express. 2017 Oct 30;7(1):192. doi: 10.1186/s13568-017-0493-z. AMB Express. 2017. PMID: 29086199 Free PMC article.
-
A cell transmembrane peptide chimeric M(27-39)-HTPP targeted therapy for hepatocellular carcinoma.iScience. 2023 Apr 29;26(5):106766. doi: 10.1016/j.isci.2023.106766. eCollection 2023 May 19. iScience. 2023. PMID: 37234089 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources